From the company that brought you CA125, Fujirebio now introduces HE4, the first new biomarker in 30 years for ovarian cancer management1
Lumipulse G HE4 is a Chemiluminescent Enzyme Immunoassay (CLEIA) for in vitro diagnostics (IVD) use for the quantitative measurement of HE4 (Human epididymis protein 4) in human serum or plasma (sodium heparin, lithium heparin, or dipotassium EDTA) on the LUMIPULSE G system.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Lumipulse® G HE4 Immunoreaction Cartridges
Product number 234068 3 × 14 Tests
Lumipulse® G HE4 Calibrators
Product number 234075 1 × 2 Concentrations
What is HE4?
Human Epididymis protein 4 (HE4), a serum biomarker, is expressed in normal epithelial tissue. HE4 is detected in high levels in the serum of ovarian cancer patients. HE4 has shown to be a stable biomarker in which levels do not change in normal physiological conditions.
HE4 is not evelevated
in any phases of the menstruation cycle or with hormonal treatments3
with hormonal stimulation during IVF treatment4
Importance of specific biomarker for management of gynecologic diseases
Cysts are a common occurrence, especially in premenopausal women, and the majority of cysts are benign:
Up to 10% of women will have some form of surgery for ovarian mass5
Preoperative differentiation between the benign and the malignant ovarian mass in the premenopausal woman is problematic6